FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Anderson Thomas (Last) (First) (Middle) C/O SAGE THERAPEUTICS, INC. 215 FIRST STREET							Issuer Name and Ticker or Trading Symbol Sage Therapeutics, Inc. [SAGE] Date of Earliest Transaction (Month/Day/Year) 12/15/2016										of Reporting Person(s) to I cable) or 10% ((give title Other below See Remarks			Owner (specify		
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)							4. If Amendment, Date of Original Filed (Month/Day/Year)										Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - No	n-Deriv	/ative	e Se	curit	ies Ac	cqui	ired, C	Disp	osed c	of, or Be	nefici	ally	Owned						
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					ar) i	2A. Deemed Execution Date, if any (Month/Day/Year)		·,	3. Transact Code (In: 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			4 and Securiti Benefic		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									\[\frac{1}{2}\]	Code \	/	Amount	(A) or (D)	Price	e	Transac (Instr. 3	tion(s)			Instr. 4)		
Common Stock 12/15/					5/2016	6				M		1,900) A	\$8	.92	1,	,900		D			
Common Stock 12/15/2					5/2016	6			Ť	F ⁽¹⁾		346	D \$		3.99	1,554			D			
		Т	able II -										, or Ben ble secu			Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transaction Code (Instr 8)		n of			Oate Exer Diration D Dirath/Day/	ate		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D S (li	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exe	e ercisable		kpiration ate	Title	Amour or Number of Shares	er							
Stock Option (Right to Buy)	\$8.92	12/15/2016			M			1,900		(2)	05	5/21/2024	Common Stock	1,900	0	\$0.00	165,138	3	D			

Explanation of Responses:

- 1. The disposition reported on this Form 4 were effected pursuant to a stock swap using existing employee stock purchase (espp) shares.
- 2. The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option shall vest in full on May 5, 2018, subject to continued service through such date.

Remarks:

Chief Commercial Strategy Officer

/s/ Anne Marie Cook, as

Attorney-in-Fact for Thomas 12/19/2016

Anderson

** Signature of Reporting Person Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.